A5077701517- Advanced Radiotherapy Techniques
- Prostate Cancer Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Brain Metastases and Treatment
- Glioma Diagnosis and Treatment
- Radiation Dose and Imaging
- Advances in Oncology and Radiotherapy
- Lung Cancer Research Studies
- Advanced X-ray and CT Imaging
- Electronic Health Records Systems
- Radiopharmaceutical Chemistry and Applications
- Radiology practices and education
- Cardiac tumors and thrombi
- Statistical Methods in Clinical Trials
- Innovations in Medical Education
- Effects of Radiation Exposure
- Clinical practice guidelines implementation
- Cardiovascular and Diving-Related Complications
- Nanoplatforms for cancer theranostics
- Nursing Diagnosis and Documentation
- Gyrotron and Vacuum Electronics Research
- Management of metastatic bone disease
- Oral health in cancer treatment
- Simulation-Based Education in Healthcare
- Nursing education and management
University of California, Los Angeles
2015-2021
UCLA Medical Center
2014-2021
UCLA Health
2020
Cedars-Sinai Medical Center
2017
Boston University
2010-2012
Purpose: To assess the optimal planning target volume (PTV) margins for stereotactic body radiotherapy (SBRT) of prostate cancer based on inter- and intra-fractional motion determined from daily image guidance. Methods Materials: 205 patients who were enrolled two prospective studies SBRT (8 Gy x 5 fractions) localized treated at a single institution between 2012 2017 had complete shift data available. All scheduled kilovoltage planar imaging during with rigid registration to intraprostatic...
<h3>Importance</h3> Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) can detect low-volume, nonlocalized (ie, regional or metastatic) prostate cancer that was occult on conventional imaging. However, the long-term clinical implications of PSMA PET/CT upstaging remain unclear. <h3>Objectives</h3> To evaluate prognostic significance a nomogram models an individual’s risk and to compare its performance with existing risk-stratification tools....
The optimal management strategy for high-risk prostate cancer and additional adverse clinicopathologic features remains unknown.To compare clinical outcomes among patients with after definitive treatment.This retrospective cohort study included (as defined by the National Comprehensive Cancer Network [NCCN]) at least 1 feature (defined as any primary Gleason pattern 5 on biopsy, T3b-4 disease, ≥50% cores biopsy results positive cancer, or NCCN ≥2 features) treated between 2000 2014 16...
Aim: We determined if pre-treatment systemic inflammation would predict poor outcomes in the setting of stereotactic radiosurgery (SRS) for brain metastases. Patients and Methods: The pretreatment albumin concentration, neutrophil lymphocyte counts, platelet-to-lymphocyte ratio (PLR) were evaluated to determine association with intracranial control, local control (LC), initial MRI response (MR), overall survival (OS) among 70 patients 152 separate metastases treated SRS alone from 2008-2015....
Locoregional recurrence in the pelvis after definitive treatment for rectal cancer can lead to significant morbidity. Furthermore, toxicity associated with reirradiation may also negatively impact quality of life and even survival. Here we present case a 39-year-old male locoregionally recurrent left pelvic sidewall lymph node, treated stereotactic magnetic resonance (MR)-guided ablative radiotherapy previously receiving long-course chemoradiation that had already exceeded ideal bowel dose...
To establish the safety and efficacy of gantry-mounted linear accelerator-based stereotactic body radiation therapy (SBRT) for low- intermediate-risk prostate cancer.We pooled 921 patients enrolled on 7 single-institution prospective phase II trials gantry-based SBRT from 2006 to 2017. The cumulative incidences biochemical recurrence (defined by Phoenix definition) physician-scored genitourinary (GU) gastrointestinal (GI) toxicities per original using Common Terminology Criteria Adverse...
To evaluate the safety of stereotactic body radiation therapy (SBRT) for prostate cancer in men with inflammatory bowel disease (IBD).We queried a consortium database patients IBD receiving SBRT between 2006 and 2012. Identified were matched without history 3:1 fashion based on dose, fractionation, use androgen deprivation therapy, age distribution. Logistic regression was used to association having experiencing acute late gastrointestinal (GI) genitourinary (GU) toxicities as scored Common...
Purpose: Dosimetric predictors of toxicity after Stereotactic Body Radiation Therapy (SBRT) are not well established. We sought to develop a multivariate model that predicts Common Terminology Criteria for Adverse Events (CTCAE) late grade 2 or greater genitourinary (GU) by interrogating the entire dose-volume histogram (DVH) from large cohort prostate cancer patients treated with SBRT on prospective trials. Methods: 339 CTCAE data were identified and analyzed. All received 40 Gy in five...
208 Background: Treatment of high risk prostate cancer (HRPCa) with external beam radiotherapy (EBRT) plus brachytherapy (BT) boost (EBRT+BT) has been prospectively associated lower rates BCR, albeit potentially increased toxicity, and retrospectively linked to decreased distant metastasis (DM) PCa-specific mortality (PCSM) compared EBRT alone. However, it is unclear whether patients who develop BCR following either approach have similar downstream oncologic outcomes. Methods: We identified...